From January 1, investors should expect negligible sales from Revlimid, CFO MV Narasimham tells Moneycontrol. In Q3, US revenues slipped by $35 million sequentially primarily due to lower Revlimid con ...
Apart from the Revlimid loss, generic price competition in the US, and the addition of new medical representatives in the ...
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results